SoniVie

Rosh Haayin, Israel Founded: 2014 • Age: 12 yrs Acquired By Boston Scientific
A denervation catheter for pulmonary hypertension treatment is developed.

About SoniVie

SoniVie is a company based in Rosh Haayin (Israel) founded in 2014 was acquired by Boston Scientific in March 2025.. SoniVie has raised $62.5 million across 2 funding rounds from investors including Boston Scientific, Andera Partners and Supernova Invest. SoniVie offers products and services including TIVUS System. SoniVie operates in a competitive market with competitors including BTG International, Pulnovo Medical, Aria CV, Adient Medical and Crux Biomedical, among others.

  • Headquarter Rosh Haayin, Israel
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Sonivie Ltd.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $62.5 M (USD)

    in 2 rounds

  • Latest Funding Round
    $60 M (USD), Series C

    Jan 09, 2023

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Boston Scientific

    (Mar 03, 2025)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of SoniVie

SoniVie offers a comprehensive portfolio of products and services, including TIVUS System. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Ultrasound-based system for renal denervation to reduce hypertension.

People of SoniVie
Headcount 10-50
Employee Profiles 7
Employee Profiles
People
Ophir Coriat
Director Of Operations
People
Jason Jones
Global Vp, Clinical Affairs
People
Yael Katzir Levy
Director Of Finance
People
Janelle J.
Clinical Affairs Director

Unlock access to complete

Funding Insights of SoniVie

SoniVie has successfully raised a total of $62.5M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $60 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series C — $60.0M
  • First Round

    (02 Nov 2015)

  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2023 Amount Series C - SoniVie Valuation Andera Partners
Nov, 2015 Amount Series A - SoniVie Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in SoniVie

SoniVie has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Boston Scientific, Andera Partners and Supernova Invest. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Capital is provided to firms for growth, buyouts, and acquisitions.
Founded Year Domain Location
-
Founded Year Domain Location
Venture capital firm
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by SoniVie

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - SoniVie

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Sonivie Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of SoniVie

SoniVie operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BTG International, Pulnovo Medical, Aria CV, Adient Medical and Crux Biomedical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics are developed for oncology, pulmonology, hematology, and anti-venom treatments.
domain founded_year HQ Location
A medical device for pulmonary hypertension treatment is developed.
domain founded_year HQ Location
Device for pulmonary hypertension
domain founded_year HQ Location
Bioabsorbable medical devices are developed for pulmonary embolism prevention.
domain founded_year HQ Location
Retrievable vena cava filters are developed to prevent pulmonary emboli.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Sonivie

Frequently Asked Questions about SoniVie

When was SoniVie founded?

SoniVie was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is SoniVie located?

SoniVie is headquartered in Rosh Haayin, Israel. It is registered at Rosh Haayin, Central District, Israel.

Who is the current CEO of SoniVie?

Tomaso Zambelli is the current CEO of SoniVie.

Is SoniVie a funded company?

SoniVie is a funded company, having raised a total of $62.5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $2.5M, raised on Nov 02, 2015.

What does SoniVie do?

SoniVie was founded in 2014 in Rosh Haayin, Israel, within the medical device sector focused on cardiovascular treatments. A therapeutic intra-vascular ultrasound catheter, known as TIVUS, is developed to target nerves in the pulmonary artery associated with disease progression. This device is inserted into the artery to selectively damage relevant nerves while avoiding contact with vessel walls or adjacent tissues, supporting non-invasive interventions for pulmonary hypertension management.

Who are the top competitors of SoniVie?

SoniVie's top competitors include Pulnovo Medical, BTG International and Aria CV.

What products or services does SoniVie offer?

SoniVie offers TIVUS System.

Who are SoniVie's investors?

SoniVie has 6 investors. Key investors include Boston Scientific, Andera Partners, Supernova Invest, Omega Funds, and TechWald Holding.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available